Table 2.
Patient demographics.
| Variable | BRCA mutation (n = 12) | No BRCA mutation (n=187) | P value |
|---|---|---|---|
| Age at testing (years) | 0.222 | ||
| <30 | 1 (8.3%) | 3 (1.6%) | |
| 31–40 | 3 (25%) | 29(15.5%) | |
| 41–50 | 2 (16.7%) | 57 (30.5%) | |
| 51–60 | 2 (16.7%) | 54 (28.8%) | |
| >60 | 4 (33.3%) | 44 (23.5%) | |
| Gender (female) | 12(100%) | 186 (99.5%) | 1 |
| Race | 0.357 | ||
| White | 11 (91.2%) | 173 (92.5%) | |
| Hispanic | 0 (0%) | 4(2.1%) | |
| Asian | 0 (0%) | 3 (1.6%) | |
| Black | 1 (8.3%) | 1 (0.5%) | |
| Ashkenazi Jewish | 0 (0%) | 3 (1.6%) | |
| Native American | 0 (0%) | 2 (1.0%) | |
| Unknown | 0 (0%) | 1 (0.5%) | |
| Histology | 0.206 | ||
| DCIS | 2 (16.7%) | 28 (14.9%) | |
| Invasive Ductal Carcinoma | 8 (66.7%) | 135 (72.2%) | |
| Invasive Lobular carcinoma | 0(0%) | 13 (3.9%) | |
| Other | 0 (0%) | 6 (3.2%) | |
| Unknown | 2 (16.7%) | 5 (2.7%) | |
| ER positive | 3 (25.0%) | 124 (66.3%) | 0.003 |
| PR positive | 3 (25.0%) | 114(60.1%) | 0.01 |
| Triple Negative | 3 (25.0%) | 33 (17.6%) | 0.521 |
| Her2 positive | 2 (16.7%) | 20(10.7%) | 0.144 |
| Clinical TNM Stage | 0.155 | ||
| Stage 0 | 1 (8.3%) | 26 (13.9%) | |
| Stage I (A-B) | 2 (16.7%) | 79 (42.2%) | |
| Stage II (A-B) | 4 (33.3%) | 59 (31.5%) | |
| Stage III (A-C) | 0(0%) | 10 (5.3%) | |
| Stage IV | 2 (16.7%) | 2 (10.7%) | |
| Unknown | 2 (16.7%) | 13 (7.0%) | |
| Bilateral breast cancer | 0(0%) | 15 (8.0%) | 1 |
| Recurrent breast cancer | 0 (0%) | 10 (5.4%) | 1 |
| Completed panel testing | 3 (25%) | 67 (35.8%) |